New Zealand markets close in 4 hours 53 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
47.69+0.54 (+1.15%)
At close: 04:00PM EDT
47.69 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close47.15
Bid47.68 x 200
Ask47.72 x 200
Day's range47.00 - 48.30
52-week range42.63 - 57.82
Avg. volume1,956,530
Market cap119.056B
Beta (5Y monthly)0.45
PE ratio (TTM)20.83
EPS (TTM)2.29
Earnings dateN/A
Forward dividend & yield2.04 (4.32%)
Ex-dividend date09 May 2024
1y target est59.12
  • Bloomberg

    Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff

    (Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenTech Giants Roar as Tesla Spikes in Late Hours: Markets WrapTesla Stock in ‘No Man’s Land’ After 43% Rout Ahead of EarningsRay Dalio’s Famous Trade Is Sputtering, Investors BailingBide

  • Zacks

    Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

    Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

  • GlobeNewswire

    Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele